FDA orders boxed warning on metaclopramide

The US Food and Drug Administration has ordered boxed warnings to be  placed on products containing metoclopramide, a drug used to treat  gastrointestinal disorders.

Long-term use of the agent, which is taken by more than two million  people in the USA, has been linked to tardive dyskinesia, a disorder  that may include involuntary and repetitive movements of the body, even  after the drug is discontinued.

Products containing the compound are sold in the form of tablets, syrups  and injections under brand names including Reglan tablets, Reglan oral  disintegrating tablets, metoclopramide oral solution and Reglan  injection.